Secondary adrenal insufficiency secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Effective measures for the secondary prevention of secondary adrenal insufficiency include patient and family members education about risks of hormone replacement therapy and dose adjustments during periods of acute illnesses. Asymptomatic patients can also wear an identification bracelet stating the name of the disease to ensure proper emergency treatment during an adrenal crisis.

Secondary Prevention

Effective measures for the secondary prevention of secondary adrenal insufficiency include:

Patient and family members involved in patient care should be properly educated about risks of hormone replacement therapy.^[1]^[2]
Patient should also be educated about dose adjustments during acute illnesses.^[3]^[4]
Asymptomatic patients can also wear an identification bracelet stating the name of the disease to ensure proper emergency treatment during an adrenal crisis.^[5]
People who have taken long-term glucocorticoids in the past should tell their doctor before surgery. These patients must be treated with intravenous glucocorticoids and saline before surgery and continue until the patient is fully awake after surgery and able to take medication by mouth.

References

↑ Tucci V, Sokari T (2014). “The clinical manifestations, diagnosis, and treatment of adrenal emergencies”. Emerg. Med. Clin. North Am. 32 (2): 465–84. doi:10.1016/j.emc.2014.01.006. PMID 24766944.
↑ Napier C, Pearce SH (2014). “Current and emerging therapies for Addison’s disease”. Curr Opin Endocrinol Diabetes Obes. 21 (3): 147–53. doi:10.1097/MED.0000000000000067. PMID 24755997.
↑ Napier C, Pearce SH (2012). “Autoimmune Addison’s disease”. Presse Med. 41 (12 P 2): e626–35. doi:10.1016/j.lpm.2012.09.010. PMID 23177474.
↑ Quinkler M (2012). “[Addison’s disease]”. Med Klin Intensivmed Notfmed (in German). 107 (6): 454–9. doi:10.1007/s00063-012-0112-3. PMID 22907517.
↑ Hahner S, Allolio B (2005). “Management of adrenal insufficiency in different clinical settings”. Expert Opin Pharmacother. 6 (14): 2407–17. doi:10.1517/14656566.6.14.2407. PMID 16259572.

Template:WikiDoc Sources

[pmid24766944-1] Tucci V, Sokari T (2014). “The clinical manifestations, diagnosis, and treatment of adrenal emergencies”. Emerg. Med. Clin. North Am. 32 (2): 465–84. doi:10.1016/j.emc.2014.01.006. PMID 24766944.

[pmid24755997-2] Napier C, Pearce SH (2014). “Current and emerging therapies for Addison’s disease”. Curr Opin Endocrinol Diabetes Obes. 21 (3): 147–53. doi:10.1097/MED.0000000000000067. PMID 24755997.

[pmid23177474-3] Napier C, Pearce SH (2012). “Autoimmune Addison’s disease”. Presse Med. 41 (12 P 2): e626–35. doi:10.1016/j.lpm.2012.09.010. PMID 23177474.

[pmid22907517-4] Quinkler M (2012). “[Addison’s disease]”. Med Klin Intensivmed Notfmed (in German). 107 (6): 454–9. doi:10.1007/s00063-012-0112-3. PMID 22907517.

[pmid16259572-5] Hahner S, Allolio B (2005). “Management of adrenal insufficiency in different clinical settings”. Expert Opin Pharmacother. 6 (14): 2407–17. doi:10.1517/14656566.6.14.2407. PMID 16259572.

[1]

[2]

[3]

[4]

[5]